
Timothy F. Cloughesy, MD, discusses the FDA approval of dordaviprone for the treatment of patients with H3K27M-mutated diffuse midline glioma.

Your AI-Trained Oncology Knowledge Connection!


Timothy F. Cloughesy, MD, is a professor and director in the Department of Neurology, Neurological Services, and the Neuro-Oncology Program; a physician in the Department of Neurology; a member of the Brain Research Institute; a member of Cancer Molecular Imaging, Nanotechnology, and Theranostics; and a member of Signal Transduction and Therapeutics at the UCLA Health Jonsson Comprehensive Cancer Center

Timothy F. Cloughesy, MD, discusses the FDA approval of dordaviprone for the treatment of patients with H3K27M-mutated diffuse midline glioma.

Timothy Cloughesy, MD, reviews data from the phase 3 INDIGO trial investigating vorasidenib in patients with residual or recurrent grade 2 glioma with an IDH1 or IDH2 mutation.